These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 34160902)
1. Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2-dependent pathway. Liu D; Liu Y; Qi B; Gu C; Huo S; Zhao B Cancer Med; 2021 Aug; 10(15):5235-5245. PubMed ID: 34160902 [TBL] [Abstract][Full Text] [Related]
2. Trichostatin A augments esophageal squamous cell carcinoma cells migration by inducing acetylation of RelA at K310 leading epithelia-mesenchymal transition. Huang K; Liu Y; Gu C; Liu D; Zhao B Anticancer Drugs; 2020 Jul; 31(6):567-574. PubMed ID: 32282366 [TBL] [Abstract][Full Text] [Related]
3. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells. Wang X; Xu J; Wang H; Wu L; Yuan W; Du J; Cai S Biochem Biophys Res Commun; 2015 Jan; 456(1):320-6. PubMed ID: 25434997 [TBL] [Abstract][Full Text] [Related]
4. Trichostatin A Inhibits Epithelial Mesenchymal Transition Induced by TGF-β1 in Airway Epithelium. Park IH; Kang JH; Shin JM; Lee HM PLoS One; 2016; 11(8):e0162058. PubMed ID: 27571418 [TBL] [Abstract][Full Text] [Related]
5. CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells. Yang L; Chang Y; Cao P Exp Cell Res; 2018 Oct; 371(1):231-237. PubMed ID: 30107147 [TBL] [Abstract][Full Text] [Related]
6. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism]. Rahimian A; Barati G; Mehrandish R; Mellati AA Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579 [TBL] [Abstract][Full Text] [Related]
7. Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability. Shen Z; Liao X; Shao Z; Feng M; Yuan J; Wang S; Gan S; Ha Y; He Z; Jie W BMC Cancer; 2019 Mar; 19(1):262. PubMed ID: 30902084 [TBL] [Abstract][Full Text] [Related]
8. Trichostatin A induces mesenchymal-like morphological change and gene expression but inhibits migration and colony formation in human cancer cells. Han RF; Li K; Yang ZS; Chen ZG; Yang WC Mol Med Rep; 2014 Dec; 10(6):3211-6. PubMed ID: 25269990 [TBL] [Abstract][Full Text] [Related]
9. The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells. Chen X; Xiao W; Chen W; Luo L; Ye S; Liu Y Cell Death Dis; 2013 Oct; 4(10):e884. PubMed ID: 24157878 [TBL] [Abstract][Full Text] [Related]
10. FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer. Hu X; Zhai Y; Kong P; Cui H; Yan T; Yang J; Qian Y; Ma Y; Wang F; Li H; Cheng C; Zhang L; Jia Z; Li Y; Yang B; Xu E; Wang J; Yang J; Bi Y; Chang L; Wang Y; Zhang Y; Song B; Li G; Shi R; Liu J; Zhang M; Cheng X; Cui Y Cancer Lett; 2017 Jul; 397():83-93. PubMed ID: 28366557 [TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest. Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863 [TBL] [Abstract][Full Text] [Related]
12. The glioma-associated oncogene homolog 1 promotes epithelial--mesenchymal transition in human esophageal squamous cell cancer by inhibiting E-cadherin via Snail. Min S; Xiaoyan X; Fanghui P; Yamei W; Xiaoli Y; Feng W Cancer Gene Ther; 2013 Jul; 20(7):379-85. PubMed ID: 23788111 [TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331 [TBL] [Abstract][Full Text] [Related]
14. 3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE Zhu P; Yu H; Zhou K; Bai Y; Qi R; Zhang S J Exp Clin Cancer Res; 2020 Jun; 39(1):113. PubMed ID: 32546278 [TBL] [Abstract][Full Text] [Related]
15. Effect of Trichostatin A on radiation induced epithelial-mesenchymal transition in A549 cells. Nagaraja SS; Krishnamoorthy V; Raviraj R; Paramasivam A; Nagarajan D Biochem Biophys Res Commun; 2017 Dec; 493(4):1534-1541. PubMed ID: 28993195 [TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. Ji M; Lee EJ; Kim KB; Kim Y; Sung R; Lee SJ; Kim DS; Park SM Oncol Rep; 2015 May; 33(5):2299-308. PubMed ID: 25813246 [TBL] [Abstract][Full Text] [Related]
17. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines. Ma J; Guo X; Zhang S; Liu H; Lu J; Dong Z; Liu K; Ming L Mol Med Rep; 2015 Jun; 11(6):4525-31. PubMed ID: 25634603 [TBL] [Abstract][Full Text] [Related]
18. Downregulation of nicotinamide N-methyltransferase inhibits migration and epithelial-mesenchymal transition of esophageal squamous cell carcinoma via Wnt/β-catenin pathway. Cui Y; Zhang L; Wang W; Ma S; Liu H; Zang X; Zhang Y; Guan F Mol Cell Biochem; 2019 Oct; 460(1-2):93-103. PubMed ID: 31278587 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of bromodomain-containing protein 4 enhances the migration of esophageal squamous cell carcinoma cells by inducing cell autophagy. Yang WQ; Liang R; Gao MQ; Liu YZ; Qi B; Zhao BS World J Gastrointest Oncol; 2022 Dec; 14(12):2340-2352. PubMed ID: 36568944 [TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells. Wang J; Xu MQ; Jiang XL; Mei XY; Liu XG Anticancer Drugs; 2018 Jan; 29(1):80-88. PubMed ID: 29176396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]